Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Phase 3CompletedNCT00150449

Pfizer511 enrolled

Overview

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

511

Conditions

Anxiety Neuroses

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have completed the double-blind portion of the preceding trial * Completed any protocol specified withdrawal phase and follow-up visits. Exclusion Criteria: * Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.

Locations (138)

Outcomes

Primary Outcomes

Safety Tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

A-1040 Wien, Austria

Pfizer Investigational Site

Vienna, Austria

Pfizer Investigational Site

Wein, Austria

Pfizer Investigational Site

Brussels, Belgium

Pfizer Investigational Site

De Pinte, Belgium

Pfizer Investigational Site

Ghent, Belgium

Pfizer Investigational Site

Kortrijk, Belgium

Pfizer Investigational Site

Lede, Belgium

Pfizer Investigational Site

Liège, Belgium

Pfizer Investigational Site

Sint-Denijs-Westrem, Belgium

...and 128 more locations